Subtype
Malignant Uterine Neoplasm
CI-CAN-00005955Explore in graph →
824 active trials7 approved drugs44 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005955Explore in graph →
Clinical trials
3,291 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (333)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06359431 | A Novel Smart Speculum Versus a Standard Speculum for Easy Visualisation of the Cervix and Performing Remote Cervical Cancer Screening | completed | N/A | 81 | GICMEDOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05123482 | A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies | recruiting | Phase 1 / Phase 2 | 460 | AstraZenecaINDUSTRY | 15 | Sep 11, 2026 | clinicaltrials |
| NCT05979493 |
| QL Block in Laparoscopic Myomectomy |
| recruiting |
| Phase 4 |
| 80 |
| Joseph Findley MDOTHER |
| 1 |
| Sep 11, 2026 |
| clinicaltrials |
| NCT07065552 | Tirzepatide in Obesity-Driven Endometrial Cancer | recruiting | Early Phase 1 | 20 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07181720 | CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors | suspended | Phase 1 | 90 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07815873 | Gut Microbiome in Patients With Lung and Melanoma Cancer and Intestinal Microbiota in Gynecologic Cancers(CERBERO) | not yet recruiting | N/A | 360 | European Institute of OncologyOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07816263 | Guaraná Supplementation for Cancer-Related Fatigue(GUARANA-CRF) | recruiting | — | 60 | Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento AnguloOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT02101775 | Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 2 | 124 | National Cancer Institute (NCI)NIH | 3 | Sep 10, 2026 | clinicaltrials |
| NCT02397083 | Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer(LEVER) | active not recruiting | Phase 2 | 102 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT04683653 | Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer | suspended | Phase 1 / Phase 2 | 100 | University of ChicagoOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT04865887 | Pembrolizumab and Lenvatinib in Advanced Cervical Cancer | recruiting | Phase 2 | 35 | Georgetown UniversityOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06293898 | Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors | recruiting | Phase 1 | 280 | SystImmune Inc.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07811375 | Perioperative Adebrelimab for Locally Advanced Cervical Cancer(ADE-LACC) | not yet recruiting | Phase 2 | 35 | Anhui Provincial HospitalOTHER_GOV | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07812636 | Tirzepatide and Levonorgestrel IUD Therapy for EIN and Early-Stage Endometrial Cancer(TIDE) | not yet recruiting | Early Phase 1 | 15 | Milton S. Hershey Medical CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07814248 | A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors | not yet recruiting | Phase 1 | 74 | TwoStep Therapeutics, Inc.INDUSTRY | 0 | Sep 10, 2026 | clinicaltrials |
| NCT00977574 | Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer | active not recruiting | Phase 2 | 349 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT03367741 | Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer | active not recruiting | Phase 2 | 82 | National Cancer Institute (NCI)NIH | 2 | Sep 9, 2026 | clinicaltrials |
| NCT03651206 | Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib(ROCSAN) | recruiting | Phase 2 / Phase 3 | 138 | ARCAGY/ GINECO GROUPOTHER | 3 | Sep 9, 2026 | clinicaltrials |
| NCT07166094 | Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer(RAINFOL-03) | recruiting | Phase 3 | 660 | GenmabINDUSTRY | 19 | Sep 9, 2026 | clinicaltrials |
| NCT02257528 | Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer | active not recruiting | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07041606 | An Observational Study of Molecular profIling of Advanced and aggRessive ENdometrial Cancer and 1-st Line Treatment Approaches in Russian Federation(IREN) | recruiting | — | 500 | AstraZenecaINDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07807345 | Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic | not yet recruiting | Phase 1 | 285 | Sutro Biopharma, Inc.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07808164 | ENPP1/cGAS (EG) and FAP Expression Profiles in Solid Tumors: An Immunohistochemical Study in a Vietnamese Cohort | recruiting | — | 162 | Tam Anh Research InstituteOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT01366144 | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | active not recruiting | Phase 1 | 94 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT02208375 | mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian | active not recruiting | Phase 1 | 159 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT04704661 | Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial | active not recruiting | Phase 1 | 51 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT05139368 | Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial Cancer(RT-PACE) | active not recruiting | N/A | 22 | University of UtahOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06465069 | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors(NEXUS-01) | recruiting | Phase 1 | 420 | Eli Lilly and CompanyINDUSTRY | 8 | Sep 4, 2026 | clinicaltrials |
| NCT01617382 | Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed(HIPEC) | recruiting | — | 125 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05521997 | Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer | not yet recruiting | Phase 2 | 42 | Washington University School of MedicineOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05950464 | Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer | recruiting | Phase 1 | 65 | National Cancer Institute (NCI)NIH | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06515613 | A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors | recruiting | Phase 1 | 156 | Context Therapeutics Inc.INDUSTRY | 2 | Sep 3, 2026 | clinicaltrials |
| NCT06989112 | DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer(DE-01) | recruiting | Phase 3 | 600 | AstraZenecaINDUSTRY | 23 | Sep 3, 2026 | clinicaltrials |
| NCT07194551 | Assessing Uterine Cancer Risk in Lynch Syndrome Carriers Using Vaginal Self-sampling and a Health Questionnaire(Lynch-SCAN) | recruiting | N/A | 30 | University of British ColumbiaOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07602842 | A Study of IDP-001 in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 132 | InduPro, Inc.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07755436 | Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer. | recruiting | Phase 1 | 180 | ArriVent BioPharma, Inc.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05334069 | Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | recruiting | — | 2,000 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05864144 | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 98 | Sensei Biotherapeutics, Inc.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06904365 | Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women(OvAR-Y) | recruiting | — | 11 | Washington University School of MedicineOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06995833 | Durvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing Surveillance | recruiting | — | 50 | AstraZenecaINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07216105 | FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 119 | Fate TherapeuticsINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07796672 | Feasibility Study of Blood Biomarker Identification in Cervical Cancer(CLARITY) | recruiting | — | 100 | Queensland Centre for Gynaecological CancerOTHER_GOV | 1 | Sep 2, 2026 | clinicaltrials |
| NCT02880007 | Dose Optimization in 3D Pulsed Dose Rate Brachytherapy for Patients With Locally Advanced Cervical Cancer(TRIDICOL) | completed | Phase 2 | 48 | Institut de Cancérologie de LorraineOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07520188 | C-3002: Enhancing Cervical Cancer Screening Access and Follow-up Care at 'CASCADE' Clinical Sites in the United States(CASCADE3002) | not yet recruiting | — | 3,500 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT04839614 | Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia | recruiting | N/A | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05458960 | Impact of Basic Needs Assessment and Support to Improve Colposcopy Show Rate(BASICS) | terminated | N/A | 3 | Washington University School of MedicineOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06669533 | Use Misoprostol to Optimize Prevention of Cervical Cancer(MISOPCx) | recruiting | N/A | 420 | University of Alabama at BirminghamOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07662824 | Flyte Device for Improving Urinary Incontinence Among Endometrial and Cervical Cancer Survivors Who Have Undergone Radiation Therapy | recruiting | N/A | 44 | Mayo ClinicOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT00867464 | Extended Follow Up of Young Women in Costa Rica Who Received Vaccine for Human Papillomavirus Types 16 and 18 and Unvaccinated Controls | active not recruiting | — | 8,670 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT01081262 | Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer | active not recruiting | Phase 3 | 50 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
Data updated 16 days agoSource updated Sep 14, 2026source: clinicaltrials